Annotation Detail for GYPE
Basic Information
Top
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| D013629 |
Tamoxifen |
Tamoxifen results in decreased expression of GYPE mRNA | decreases expression | 15590111
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D000008 |
Abdominal Neoplasms |
|
Tamoxifen |
5.96 | 14745880 |
| MESH:D001943 |
Breast Neoplasms |
|
Tamoxifen |
2.16 | 19084267 19059307 15668708 16873071 19189212 19289846 20544844 17242785 16202921 20390343 19189210 20859285 19142967 21152245 20135344 18984771 19115204 17440819 15565566 19487384 18351453 19066611 19155303 16818667 19221464 19103187 17893378 19244106 18815881 18997820 19011961 18821012 11161223 19200415 20065188 16273361 18629630 17049068 18855134 20005174 17261762 21138602 19288272 18425577 19410462 |
| MESH:D018270 |
Carcinoma, Ductal, Breast |
|
Tamoxifen |
5.41 | 19066611 |
| MESH:D006528 |
Carcinoma, Hepatocellular |
|
Tamoxifen |
1.86 | 16924424 |
| MESH:D002295 |
Carcinoma, Transitional Cell |
|
Tamoxifen |
4.19 | 17572228 |
| MESH:D003711 |
Demyelinating Diseases |
|
Tamoxifen |
5.27 | 19031437 |
| MESH:D003928 |
Diabetic Nephropathies |
|
Tamoxifen |
4.00 | 19279558 |
| MESH:D004681 |
Encephalomyelitis, Autoimmune, Experimental |
|
Tamoxifen |
4.32 | 19031437 |
| MESH:D016889 |
Endometrial Neoplasms |
|
Tamoxifen |
3.37 | 20544844 19155303 17893378 16202921 |
| MESH:D005234 |
Fatty Liver |
|
Tamoxifen |
3.79 | 14986274 19224547 |
| MESH:D052776 |
Female Urogenital Diseases |
|
Tamoxifen |
3.52 | 16709447 |
| MESH:D018221 |
Fibromatosis, Abdominal |
|
Tamoxifen |
5.62 | 14745880 |
| MESH:D018222 |
Fibromatosis, Aggressive |
|
Tamoxifen |
5.27 | 19069698 |
| MESH:D007249 |
Inflammation |
|
Tamoxifen |
2.59 | 19457130 |
| MESH:D007680 |
Kidney Neoplasms |
|
Tamoxifen |
3.53 | 18625569 |
| MESH:D008064 |
Lipidoses |
|
Tamoxifen |
3.53 | 15342952 17567588 |
| MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Tamoxifen |
1.75 | 18564211 |
| MESH:D008113 |
Liver Neoplasms |
|
Tamoxifen |
2.37 | 16684651 |
| MESH:D008175 |
Lung Neoplasms |
|
Tamoxifen |
1.75 | 18625569 |
| MESH:D015674 |
Mammary Neoplasms, Animal |
|
Tamoxifen |
4.85 | 19428831 |
| MESH:D008325 |
Mammary Neoplasms, Experimental |
|
Tamoxifen |
2.94 | 14580682 16827153 11731420 19196722 19196723 |
| MESH:D020149 |
Manganese Poisoning |
|
Tamoxifen |
5.96 | 19453300 |
| MESH:D008545 |
Melanoma |
|
Tamoxifen |
1.93 | 19393235 12393984 |
| MESH:D018328 |
Melanoma, Amelanotic |
|
Tamoxifen |
5.27 | 15990972 |
| MESH:D009362 |
Neoplasm Metastasis |
|
Tamoxifen |
2.71 | 19393235 |
| MESH:D009364 |
Neoplasm Recurrence, Local |
|
Tamoxifen |
2.64 | 19410462 |
| MESH:D009376 |
Neoplasms, Hormone-Dependent |
|
Tamoxifen |
5.41 | 19189210 19200415 19196722 |
| MESH:D011471 |
Prostatic Neoplasms |
|
Tamoxifen |
3.07 | 15067354 |
| MESH:D013088 |
Spermatocele |
|
Tamoxifen |
5.71 | 16709447 |
| MESH:D013119 |
Spinal Cord Injuries |
|
Tamoxifen |
5.13 | 19457130 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
Tamoxifen |
2.51 | 16712894 17572228 8653321 |
Related Pathway Information